NCT05221320: A trial that was reported late by BioMed Valley Discoveries, Inc
This trial has reported, although it was 71 days late in doing so.
Full data
| Full entry on ClinicalTrials.gov | NCT05221320 |
|---|---|
| Title | A Phase 2 Basket Trial of Ulixertinib (BVD-523) in Combination With Hydroxychloroquine in Patients With Advanced GI Malignancies Harboring Mitogen-activated Protein Kinase (MAPK) Pathway Mutations (BVD-523-HCQ) |
| Results Status | Reported (late) |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | May 26, 2022 |
| Completion date | May 8, 2024 |
| Required reporting date | May 8, 2025, midnight |
| Actual reporting date | July 18, 2025 |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | 71 |